Being tested
Foralumab: slow disability worsening in secondary progressive MS
secondary progressive MS · Cell therapies and tolerisation
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 1
- Running now
- 1
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 54
How the verdict was reached
No result yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Foralumab, phase 2 | Phase 2 | 54 | 2023 | Still running | Will count when it reports |
Counted: 0. Will count later: 1. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Nov 2026First listed as Being tested
Related hypotheses
- Cell therapies and tolerisation: protect nerve tissue in secondary progressive MS
- Cell therapies and tolerisation: repair myelin in secondary progressive MS
- Cell therapies and tolerisation: reset the immune system for lasting remission in secondary progressive MS
- Cell therapies and tolerisation: slow disability worsening in secondary progressive MS
- Dirucotide: slow disability worsening in secondary progressive MS
- Evruleucel: slow disability worsening in secondary progressive MS
- Rildinadstrocel: slow disability worsening in secondary progressive MS
- Cell therapies and tolerisation: reduce relapses and new lesions in secondary progressive MS
Assembled by software from public sources.